A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Panobinostat (Primary) ; Sirolimus; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 20 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 18 May 2017 Planned number of patients changed from 44 to 64.
- 25 Feb 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.